Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Nuggehally R Srinivas. (2018) Extrapolation of Pharmacokinetic Interaction Data of Proton Pump Inhibitors Obtained in Healthy Subjects for Oral Targeted Therapies in Cancer Patients. International Journal of Pharmacokinetics 3:3, pages 93-97.
Read now
Read now
Justin D Lutz & Nina Isoherranen. (2012) In vitro-to-in vivo predictions of drug–drug interactions involving multiple reversible inhibitors. Expert Opinion on Drug Metabolism & Toxicology 8:4, pages 449-466.
Read now
Read now
Bo Wang, Li-Ping Yang, Xiao-Zhuang Zhang, Shui-Qing Huang, Mark Bartlam & Shu-Feng Zhou. (2009) New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metabolism Reviews 41:4, pages 573-643.
Read now
Read now
Tracey D. Bradshaw & David R. Bell. (2009) Relevance of the aryl hydrocarbon receptor (AhR) for clinical toxicology. Clinical Toxicology 47:7, pages 632-642.
Read now
Read now
K. H. Liu, M. J. Kim, J. H. Shon, Y. S. Moon, S. Y. Seol, W Kang, I. J. Cha & J. G. Shin. (2005) Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro. Xenobiotica 35:1, pages 27-38.
Read now
Read now
Articles from other publishers (45)
Elvira Ingrid Levy, Sebastien Kindt, Melina Simon & Yvan Vandenplas. 2022. Gastroesophageal Reflux in Children. Gastroesophageal Reflux in Children
307
318
.
Stanley L. Marks, Peter H. Kook, Mark G. Papich, M. K. Tolbert & Michael D. Willard. (2018) ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats. Journal of Veterinary Internal Medicine 32:6, pages 1823-1840.
Crossref
Crossref
Naomi Rozentul, Yosef Avrahami, Moran Shubely, Laura Levy, Anna Munder, Guy Cohen, Erol Cerasi, Shlomo Sasson & Arie Gruzman. (2017) A Novel Phenylchromane Derivative Increases the Rate of Glucose Uptake in L6 Myotubes and Augments Insulin Secretion from Pancreatic Beta-Cells by Activating AMPK. Pharmaceutical Research 34:12, pages 2873-2890.
Crossref
Crossref
Nicole Rüger, Georg Michael Fassauer, Christian Bock, Thomas Emmrich, Anja Bodtke & Andreas Link. (2016) Substituted tetrazoles as multipurpose screening compounds. Molecular Diversity 21:1, pages 9-27.
Crossref
Crossref
Anil Darbari, Sona Sehgal, Nidhi Rawal & Rachel Imhoff. 2017. Esophageal and Gastric Disorders in Infancy and Childhood. Esophageal and Gastric Disorders in Infancy and Childhood
971
978
.
Lyndsey L. Anderson, Eric J. Berns, Pradeep Bugga, Alfred L. GeorgeJr.Jr. & Milan Mrksich. (2016) Measuring Drug Metabolism Kinetics and Drug–Drug Interactions Using Self-Assembled Monolayers for Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry. Analytical Chemistry 88:17, pages 8604-8609.
Crossref
Crossref
Y Shirasaka, A S Chaudhry, M McDonald, B Prasad, T Wong, J C Calamia, A Fohner, T A Thornton, N Isoherranen, J D Unadkat, A E Rettie, E G Schuetz & K E Thummel. (2015) Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. The Pharmacogenomics Journal 16:4, pages 375-387.
Crossref
Crossref
Charles W. O’Connell, Amir A. Schricker, Aaron B. Schneir, Imir G. Metushi, Ulrika Birgersdotter-Green & Alicia B. Minns. (2016) High-dose loperamide abuse–associated ventricular arrhythmias. HeartRhythm Case Reports 2:3, pages 232-236.
Crossref
Crossref
Daniel R. Lasoff & Aaron Schneir. (2016) Ventricular Dysrhythmias from Loperamide Misuse. The Journal of Emergency Medicine 50:3, pages 508-509.
Crossref
Crossref
Tao Zhang. (2015) Physiologically based pharmacokinetic modeling of disposition and drug–drug interactions for atorvastatin and its metabolites. European Journal of Pharmaceutical Sciences 77, pages 216-229.
Crossref
Crossref
Shlomi Cohen, Mirjam Bueno de Mesquita & Francis B. Mimouni. (2015) Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review. British Journal of Clinical Pharmacology 80:2, pages 200-208.
Crossref
Crossref
Chuan Tian, Lixin Zhu, Dan Yu, Zhiwei Cao, Tingguo Kang & Ruixin Zhu. (2014)
The Stereoselectivity of
CYP
2C19 on R‐ and S‐isomers of Proton Pump Inhibitors
. Chemical Biology & Drug Design 83:5, pages 610-621.
Crossref
Crossref
S. Keil, S. Iwersen-Bergmann, A. Müller & H. Andresen-Streichert. (2014) Pharmakokinetische Wechselwirkungen illegaler Drogen mit ArzneimittelnPharmacokinetic interactions between pharmaceutical and illegal drugs. Rechtsmedizin 24:2, pages 77-90.
Crossref
Crossref
D. E. Moody, F. Liu & W. B. Fang. (2013) In vitro Inhibition of Methadone and Oxycodone Cytochrome P450-Dependent Metabolism: Reversible Inhibition by H2-Receptor Agonists and Proton-Pump Inhibitors. Journal of Analytical Toxicology 37:8, pages 476-485.
Crossref
Crossref
Yunfeng Tie, Brooks McPhail, Huixiao Hong, Bruce A. Pearce, Laura K. Schnackenberg, Weigong Ge, Dan A. Buzatu, Jon G. Wilkes, James C. Fuscoe, Weida Tong, Bruce A. Fowler, Richard D. Beger & Eugene Demchuk. (2012) Modeling Chemical Interaction Profiles: II. Molecular Docking, Spectral Data-Activity Relationship, and Structure-Activity Relationship Models for Potent and Weak Inhibitors of Cytochrome P450 CYP3A4 Isozyme. Molecules 17:3, pages 3407-3460.
Crossref
Crossref
Gabriele M. Böhmer, Christoph H. Gleiter, Klaus Mörike, Nassr Nassr, Antje Walz & Gezim Lahu. (2011) No Dose Adjustment on Coadministration of the PDE4 Inhibitor Roflumilast With a Weak CYP3A, CYP1A2, and CYP2C19 Inhibitor: An Investigation Using Cimetidine. The Journal of Clinical Pharmacology 51:4, pages 594-602.
Crossref
Crossref
G.P. MILLER. (2010) Warfarin therapy: how the less interesting half just got interesting. Journal of Thrombosis and Haemostasis 8:12, pages 2705-2707.
Crossref
Crossref
Chun–Ying Wu, Francis Ka–Leung Chan, Ming–Shiang Wu, Ken N. Kuo, Chang–Bi Wang, Chen–Rong Tsao & Jaw–Town Lin. (2010) Histamine2-Receptor Antagonists Are an Alternative to Proton Pump Inhibitor in Patients Receiving Clopidogrel. Gastroenterology 139:4, pages 1165-1171.e4.
Crossref
Crossref
Leila Chebane, Neda Tavassoli, Haleh Bagheri & Jean-LouisMontastruc. (2010) Hyperglycémies d’origine médicamenteuse : étude dans la Base Nationale Française de PharmacoVigilance (BNPV). Therapies 65:5, pages 447-458.
Crossref
Crossref
Sean Ekins, Andrej Bugrim, Yuri Nikolsky & Tatiana Nikolskaya. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
61
.
James M. Mullin, Melissa Gabello, Lisa J. Murray, Christopher P. Farrell, Jillan Bellows, Kevin R. Wolov, Keith R. Kearney, David Rudolph & James J. Thornton. (2009) Proton pump inhibitors: actions and reactions. Drug Discovery Today 14:13-14, pages 647-660.
Crossref
Crossref
K Singh, L Dickinson, A Chaikan, D Back, C Fletcher, A Pozniak, G Moyle, M Nelson, B Gazzard, D Herath & M Boffito. (2007) Pharmacokinetics and Safety of Saquinavir/Ritonavir and Omeprazole in HIV-infected Subjects. Clinical Pharmacology & Therapeutics 83:6, pages 867-872.
Crossref
Crossref
Trino Baptista, Yamily ElFakih, Euderruh Uzcátegui, Ignacio Sandia, Eduardo Tálamo, Enma Araujo de Baptista & Serge Beaulieu. (2008) Pharmacological Management of Atypical Antipsychotic-Induced Weight Gain. CNS Drugs 22:6, pages 477-495.
Crossref
Crossref
P. A. H. M. WIJNEN, R. A. M. OP DEN BUIJSCH, M. DRENT, P. M. J. C. KUIPERS, C. NEEF, A. BAST, O. BEKERS & G. H. KOEK. (2007) Review article: the prevalence and clinical relevance of cytochrome P450 polymorphisms. Alimentary Pharmacology & Therapeutics 26:s2, pages 211-219.
Crossref
Crossref
Gary H. Wynn, Neil B. Sandson & Kelly L. Cozza. (2007) Gastrointestinal Medications. Psychosomatics 48:1, pages 79-85.
Crossref
Crossref
Lauren A. Trepanier. (2006) Cytochrome P450 and Its Role in Veterinary Drug Interactions. Veterinary Clinics of North America: Small Animal Practice 36:5, pages 975-985.
Crossref
Crossref
Alan Winston, David Back, Carl Fletcher, Lesley Robinson, Jennifer Unsworth, Izabela Tolowinska, Malte Schutz, Anton L Pozniak, Brian Gazzard & Marta Boffito. (2006) Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS 20:10, pages 1401-1406.
Crossref
Crossref
Akihiro Ohnishi, Shigeto Murakami, Setsuko Akizuki, Junko Mochizuki, Hirotoshi Echizen & Ichiro Takagi. (2013)
In Vivo
Metabolic Activity of CYP2C19 and CYP3A in Relation to CYP2C19 Genetic Polymorphism in Chronic Liver Disease
. The Journal of Clinical Pharmacology 45:11, pages 1221-1229.
Crossref
Crossref
Wim P.D. Lemahieu, Bart D. Maes, Kristin Verbeke & Yves Vanrenterghem. (2005) Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: Consequences for FK506 assimilation. Kidney International 67:3, pages 1152-1160.
Crossref
Crossref
Catherine Litalien, Yves Th??or??t & Christophe Faure. (2005) Pharmacokinetics of Proton Pump Inhibitors in Children. Clinical Pharmacokinetics 44:5, pages 441-466.
Crossref
Crossref
Xue-Qing Li, Tommy B. Andersson, Marie Ahlström & Lars Weidolf. (2004) COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES. Drug Metabolism and Disposition 32:8, pages 821-827.
Crossref
Crossref
Shigeru Furuta, Emiko Kamada, Takeshi Omata, Tohru Sugimoto, Yoshihiro Kawabata, Keiko Yonezawa, Xiaochun Cheryl Wu & Tadashi Kurimoto. (2004) Drug–drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338. European Journal of Pharmacology 497:2, pages 223-231.
Crossref
Crossref
Nadeem H. Bhanji & Howard C. Margolese. (2012) Extrapyramidal Symptoms Related to Adjunctive Nizatidine Therapy in an Adolescent Receiving Quetiapine and Paroxetine. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 24:7, pages 923-925.
Crossref
Crossref
Maria Madeira, Marc Levine, Thomas K. H. Chang, Ahmad Mirfazaelian & Gail D. Bellward. (2004)
THE EFFECT OF CIMETIDINE ON DEXTROMETHORPHAN
O
-DEMETHYLASE ACTIVITY OF HUMAN LIVER MICROSOMES AND RECOMBINANT CYP2D6
. Drug Metabolism and Disposition 32:4, pages 460-467.
Crossref
Crossref
Susan M. Abdel-Rahman, Franklin K. Johnson, James D. Connor, Annamaria Staiano, Christophe Dupont, Vasundhara Tolia, Harland Winter, Ginette Gauthier-Dubois & Gregory L. Kearns. (2004) Developmental Pharmacokinetics and Pharmacodynamics of Nizatidine. Journal of Pediatric Gastroenterology and Nutrition 38:4, pages 442-451.
Crossref
Crossref
Susan M. Abdel‐Rahman, Franklin K. Johnson, James D. Connor, Annamaria Staiano, Christophe Dupont, Vasundhara Tolia, Harland Winter, Ginette Gauthier‐Dubois & Gregory L. Kearns. (2004) Developmental Pharmacokinetics and Pharmacodynamics of Nizatidine. Journal of Pediatric Gastroenterology and Nutrition 38:4, pages 442-451.
Crossref
Crossref
David J. Granville, Babak Tashakkor, Cindy Takeuchi, Åsa B. Gustafsson, Chengqun Huang, M. Richard Sayen, Paul WentworthJr.Jr., Mark Yeager & Roberta A. Gottlieb. (2004) Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proceedings of the National Academy of Sciences 101:5, pages 1321-1326.
Crossref
Crossref
Graham Scott, Christine Vinluan Reynolds, Slavica Milosavljev, Wayne Langholff, Magdy Shenouda & Christiane Rordorf. (2004) Lack of Effect of Omeprazole or of an Aluminium Hydroxide/Magnesium Hydroxide Antacid on the Pharmacokinetics of Lumiracoxib. Clinical Pharmacokinetics 43:5, pages 341-348.
Crossref
Crossref
Trino Baptista, N M K Ng Ying Kin & Serge Beaulieu. (2004) Treatment of the Metabolic Disturbances Caused by Antipsychotic Drugs. Clinical Pharmacokinetics 43:1, pages 1-15.
Crossref
Crossref
Chi‐Un Pae, Jung‐Jin Kim, Kyung‐Uk Lee, Chang‐Uk Lee, Won‐Myong Bahk, Soo‐Jung Lee, Chul Lee & In‐Ho Paik. (2003) Effect of nizatidine on olanzapine‐associated weight gain in schizophrenic patients in Korea: a pilot study. Human Psychopharmacology: Clinical and Experimental 18:6, pages 453-456.
Crossref
Crossref
Akio Suzuki, Izumi Iida, Mitsuyo Hirota, Masayuki Akimoto, Shohei Higuchi, Toshio Suwa, Masayoshi Tani, Takashi Ishizaki & Kan Chiba. (2003) CYP Isoforms Involved in the Metabolism of Clarithromycin in vitro: Comparison between the Identification from Disappearance Rate and that from Formation Rate of Metabolites. Drug Metabolism and Pharmacokinetics 18:2, pages 104-113.
Crossref
Crossref
Susan M. Abdel‐Rahman, Franklin K. Johnson, Neil Manowitz, Gregory B. Holmes & Gregory L. Kearns. (2013) Single‐Dose Pharmacokinetics of Nizatidine (Axid®) in Children. The Journal of Clinical Pharmacology 42:10, pages 1089-1096.
Crossref
Crossref
Shigeru Furuta, Nobuyoshi Akagawa, Emiko Kamada, Akio Hiyama, Yoshihiro Kawabata, Nobuhiko Kowata, Atsuhiro Inaba, Anne Matthews, Michael Hall & Tadashi Kurimoto. (2002) Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti‐inflammatory drug, and its lack of clinically significant CYP inhibition potential. British Journal of Clinical Pharmacology 54:3, pages 295-303.
Crossref
Crossref
U. Werneke, D. Taylor & T.A.B. Sanders. (2002) Options for pharmacological management of obesity in patients treated with atypical antipsychotics. International Clinical Psychopharmacology 17:4, pages 145-160.
Crossref
Crossref
F Caballero, E Gerez, A Batlle & E Vazquez. (2002) Interaction of cimetidine with P450 in a mouse model of hepatocarcinogenesis initiation. British Journal of Cancer 86:4, pages 630-635.
Crossref
Crossref